RFM
NBIX icon

Royal Fund Management’s Neurocrine Biosciences NBIX Stock Holding History

Royal Fund Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-83
Closed -$6K – 642
2017
Q4 		$6K Buy
+83
New +$5.66K ﹤0.01% 456

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Royal Fund Management's NBIX Position: Q1 2018 in Review

Royal Fund Management sold out of Neurocrine Biosciences (NBIX) in Q1 2018, closing a stake of 83 shares — an estimated $6K sold.

Royal Fund Management first reported a position in NBIX in Q4 2017 and held it in 1 quarter. The position peaked at $6K in Q4 2017. 266 funds tracked by Wall St. Rank hold NBIX as of Q1 2018.

  • Royal Fund Management reported no remaining Neurocrine Biosciences position as of Q1 2018 after selling out during the quarter.
  • Royal Fund Management sold 83 Neurocrine Biosciences shares in Q1 2018, an estimated $6K.
  • Royal Fund Management first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 1 quarter.
  • Royal Fund Management's Neurocrine Biosciences position peaked at $6K in Q4 2017.
  • 266 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2018.

Based on Royal Fund Management's 13F filing for Q1 2018, filed 7 May 2020.